Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Structure Patients treated with tesamorelin for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
These studies have shown, for example, that patients with type II diabetes (T2D) exhibit a higher prevalence of dementia and cancer, with men showing a particularly elevated risk of Alzheimers disease 3,4
Lancet 390 (10113), 26272642 (2017)
E., Tariq, M
